Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme
Author
Khan, F.
Ottensmeier, C.
Popat, S.
Dua, D.
Dorey, Nicole
Ellis, S.
Szabo, M.
Upadhyay, S.
Califano, R.
Chan, S.
Lee, L.
Ali, C. W.
Nicolson, M.
Bates, A. T.
Button, M.
Chaudhuri, A.
Mulvenna, P.
Shaw, H. M.
Danson, S. J.
Date
2014-07-01Journal
European journal of cancerType
Journal ArticleMulticenter Study
Publisher
ElsevierDOI
10.1016/j.ejca.2014.03.001Metadata
Show full item recordAbstract
INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. PATIENTS AND METHODS: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. RESULTS: Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. CONCLUSIONS: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.